175 related articles for article (PubMed ID: 36899911)
1. The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth.
Pant K; Richard S; Peixoto E; Yin J; Seelig DM; Carotenuto P; Salati M; Franco B; Roberts LR; Gradilone SA
Cells; 2023 Feb; 12(5):. PubMed ID: 36899911
[TBL] [Abstract][Full Text] [Related]
2. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Nagaya M; Hara H; Kamiya T; Adachi T
Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
[TBL] [Abstract][Full Text] [Related]
4. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Bruzzone S; Fruscione F; Morando S; Ferrando T; Poggi A; Garuti A; D'Urso A; Selmo M; Benvenuto F; Cea M; Zoppoli G; Moran E; Soncini D; Ballestrero A; Sordat B; Patrone F; Mostoslavsky R; Uccelli A; Nencioni A
PLoS One; 2009 Nov; 4(11):e7897. PubMed ID: 19936064
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
[TBL] [Abstract][Full Text] [Related]
6. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
[TBL] [Abstract][Full Text] [Related]
7. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
8. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
10. Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer.
Liu HY; Wang FH; Liang JM; Xiang YY; Liu SH; Zhang SW; Zhu CM; He YL; Zhang CH
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2743-2756. PubMed ID: 35776198
[TBL] [Abstract][Full Text] [Related]
11. NAD metabolism fuels human and mouse intestinal inflammation.
Gerner RR; Klepsch V; Macheiner S; Arnhard K; Adolph TE; Grander C; Wieser V; Pfister A; Moser P; Hermann-Kleiter N; Baier G; Oberacher H; Tilg H; Moschen AR
Gut; 2018 Oct; 67(10):1813-1823. PubMed ID: 28877980
[TBL] [Abstract][Full Text] [Related]
12. FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.
Zhang B; Shi D; Zhang X; Liang G; Liu W; Qiao S
Oncol Lett; 2018 Dec; 16(6):7231-7238. PubMed ID: 30546461
[TBL] [Abstract][Full Text] [Related]
13. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
14. NAMPT inhibition reduces macrophage inflammation through the NAD+/PARP1 pathway to attenuate liver ischemia-reperfusion injury.
Lu J; Wang M; Chen Y; Song H; Wen D; Tu J; Guo Y; Liu Z
Chem Biol Interact; 2023 Jan; 369():110294. PubMed ID: 36460127
[TBL] [Abstract][Full Text] [Related]
15. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor.
Kozako T; Aikawa A; Ohsugi T; Uchida YI; Kato N; Sato K; Ishitsuka K; Yoshimitsu M; Honda SI
Eur J Pharmacol; 2019 Dec; 865():172738. PubMed ID: 31614144
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial rewiring drives metabolic adaptation to NAD(H) shortage in triple negative breast cancer cells.
Carreira ASA; Ravera S; Zucal C; Thongon N; Caffa I; Astigiano C; Bertola N; Buongiorno A; Roccuzzo M; Bisio A; Pardini B; Nencioni A; Bruzzone S; Provenzani A
Neoplasia; 2023 Jul; 41():100903. PubMed ID: 37148658
[TBL] [Abstract][Full Text] [Related]
17. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
Xu R; Yuan Z; Yang L; Li L; Li D; Lv C
Oncol Rep; 2017 Sep; 38(3):1767-1773. PubMed ID: 28714034
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
